A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: To evaluate real-world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short-term efficacy. MATERIALS AND METHODS: This retrospective study included obese patients treated with the weekly injectable semagl…
In Spain, it is estimated that the prevalence of chronic kidney disease (CKD) is 7-30%. CKD is associated with a significant risk of kidney disease progression, as well as cardiovascular complications and death. CKD is currently underdiagnosed, which…
Aim To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diab…
INTRODUCTION: Obesity poses an increasing threat to U.S. military readiness, with over half of active-duty service members classified as overweight and up to 27% with obesity. Within the Military Health System (MHS), obesity contributes to service di…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent worldwide, contributing to rising morbidity and mortality. In the United States, MASLD is among the most common chronic liver diseases, affecting an estimated…
UNLABELLED: The use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for weight loss is increasing; implications in breast cancer survivors remain unclear. This retrospective cohort study evaluated treatment patterns, weight loss, and outcomes…
The global increase in obesity highlights the need for accurate tools to assess body composition and monitor treatment efficacy. Traditional metrics, including body mass index and waist circumference, offer limited precision for fat quantification. I…
INTRODUCTION: We hypothesised that an exposure-response weight predictor algorithm developed from randomised controlled trial data can predict long-term individual body weight changes in both men and women in response to subcutaneous semaglutide trea…
BACKGROUND: Prediabetes refers to the transitional stage from normal glucose metabolism to diabetes. The International Diabetes Federation guidelines reported that, as of 2024, approximately 1.12 billion people globally were in the prediabetes stage.…
AIMS: The objective of this analysis was to identify the 6-month discontinuation rate for GLP-1 analogues, reasons for discontinuation, and characteristics associated with discontinuation. MATERIALS AND METHODS: This was a retrospective analysis of a…
A decline in mortality due to heart failure (HF) with reduced ejection fraction (HFrEF) has been attributed to effective guideline-directed medical therapies. But few effective therapies are available for HF with preserved ejection fraction (HFpEF),…
(GIP), once the overlooked sibling of the incretin family, is now experiencing a research renaissance. Historically, its therapeutic development was hindered by a seemingly diminished insulinotropic effect in t(T2DM), its paradoxical stimulation of g…
OBJECTIVE: To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formula…
A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA). Despite these measures, substan…
BACKGROUND: Liver transplant recipients face high risks of cardiometabolic events after transplant, driven by posttransplant weight gain, diabetes, hypertension, as well as immunosuppression-related side effects. Glucagon-like peptide-1 receptor agon…
The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (…
Metabolic dysfunction associated steatotic liver disease (MASLD) affects nearly one-third of adults worldwide, particularly among individuals with obesity or type 2 diabetes, and in 10-30% progresses to metabolic dysfunction associated steatohepatiti…
Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-ye…